The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to obinutuzumab (Genentech), a CD20-directed cytolytic antibody, for the treatment of adults with lupus nephritis. The designation was based on data from the phase 2 NOBILITY study that compared the efficacy and safety of obinutuzumab, in combination with mycophenolate mofetil (MMF) or mycophenolic acid…
In a small study, patients with lupus nephritis who underwent renal transplantation had 5-year graft and patient survival rates of 76.3% and 92.5%, respectively.
Investigators examined racial/ethnic differences in manifestations of lupus and in the timing and risk of developing severe manifestations.
Deaths among blacks occur sooner after diagnosis and at younger age compared with whites
More adverse childhood experiences associated with depression, poor overall health for those with SLE
Patients with systemic lupus erythematosus were at greater risk for fractures compared with controls.
Complete response to induction therapy is associated with significant 82% decreased odds of death at 12 months.
In a nationwide study, renal transplant recipients with lupus nephritis had a 70% lower risk for all-cause mortality than nonrecipients.
Using electrochemiluminescence, researchers found 5 urinary proteins that have “reasonable specificity” for lupus nephritis.
Researchers observed comparable long-term outcomes between patients with late- and early-onset lupus nephritis.
